RFAI RF Acquisition Corp II

CIK 0002012807 7 ready 8-Ks latest November 14, 2025, 6:59 PM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline

Ready 8-Ks 7

Latest filing November 14, 2025, 6:59 PM ET

Top materiality 0.85

Event mix other_material ×2 · leadership ×2 · other ×2

Sentiment 0 pos · 1 neg · 6 neu

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for RFAI

Highest-materiality recent filing

RF Acquisition Corp II to merge with Nanyang Biologics in $1.5B SPAC deal; NYB to list on Nasdaq

October 2, 2025, 7:59 PM ET M&A materiality 0.85 neutral item 1.01 item 9.01

Business Combination Agreement signed Oct 2, 2025; RFAC II will merge into PubCo, then amalgamate with Nanyang.
Implied enterprise value of $1.5 billion for Nanyang Biologics, an AI drug discovery platform.

November 14, 2025, 6:59 PM ET other material materiality 0.80 negative item 1.01 item 5.03 item 5.07 item 8.01 item 9.01 ◈ Governance Changes

RFAC extends SPAC deadline to Aug 2026; ~$71.6M redeemed from trust

Shareholders approved up to 9 monthly extensions from Nov 15, 2025 to Aug 15, 2026 for business combination.
October 2, 2025, 7:59 PM ET M&A materiality 0.85 neutral item 1.01 item 9.01

RF Acquisition Corp II to merge with Nanyang Biologics in $1.5B SPAC deal; NYB to list on Nasdaq

Business Combination Agreement signed Oct 2, 2025; RFAC II will merge into PubCo, then amalgamate with Nanyang.
May 28, 2024, 7:59 PM ET other material materiality 0.65 neutral item 3.02 item 8.01 item 9.01

RF Acquisition Corp II completes $100M IPO and overallotment; trust holds $115.6M

IPO of 10,000,000 units at $10.00 per unit generated $100M gross proceeds.

Appointed

Class I director

RFAI · RF Acquisition Corp II

On May 1, 2025, Tuan Lee Low was appointed to the board of directors (the “Board”) of RF Acquisition Corp II (the “Company”) as a Class I director

Max materiality 0.85 · Median 0.50 · Most common event other_material

0 positive 1 negative 6 neutral